Welcome Guest
Home » Reports » Modular Facilities in Pharmaceutical / Biotechnology Industry, 2017-2030

Modular Facilities in Pharmaceutical / Biotechnology Industry, 2017-2030

Published: Oct 06, 2017
Pages: 250
Product Code: RA10091
License Type :  (Learn More)

 

The business strategies and operational processes in the pharmaceutical industry have regularly evolved over time. Over the past few years, there has been an increased pressure on drug manufacturers to optimize drug development costs and speed up the drug development process. Specifically, with the rise of personalized therapies and orphan drugs, manufacturers are now expected to produce significantly low volumes of a wide range of drugs owing to the patient specific nature of such therapies. In addition, with the increasing number of biosimilars in the pipeline, companies are aiming to reduce the time to market in order to ensure faster patient access. In general, the current market scenario demands the existing operational modes to be altered in such a way that the focus shifts to faster processes, lower manufacturing costs and smaller batch sizes.

 

Modular facilities have demonstrated tremendous potential in several fields; specifically, the shorter time taken to establish such facilities has a significant impact on expediting various operational processes. Over the years, the interest in such facilities has also gradually risen amongst drug manufacturers within the pharmaceutical and biopharmaceutical industries. In fact, various companies have already transitioned from establishing conventional manufacturing facilities (focused on the large-scale production of a single product) to using small, flexible and modular facilities that can handle multiple products, simultaneously. It has been reported that the time required for the construction of modular facilities, starting from design to approval, could be reduced to half the time required for the construction of conventional facilities. This is primarily due to the fact that modular buildings (modules) are typically constructed offsite, transported to the site and then assembled into fully functional entities. As a consequence of the approach used, facility construction, site preparation and regulatory documentation can proceed in parallel. This is very different from the traditional approach where the aforementioned activities have to be performed sequentially. 

 

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The ‘Modular Facilities in the Pharmaceutical / Biotechnology Industry, 2017-2030 report provides an extensive studyon the current market landscape and future outlook of modular facility manufacturers that cater to the demands of pharmaceutical and biopharmaceutical companies. The study presents an in-depth analysis of a diverse set of companies that provide complete modular facilities and / or modular cleanrooms to drug researchers / developers. In addition to other elements, the report features:

  • A review of the competitive market landscape of modular facility / modular cleanroom manufacturers with information on their geographical location (North America, Europe, Asia Pacific and rest of the world), establishment year, size (small-sized, mid-sized or large-sized) and type of industries served (pharmaceutical, biotechnology or others). It also includes information on regulatory certifications and recent projects undertaken by these companies.
  • Elaborate profiles of established players that offer a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries; each profile includes a brief overview of the company, information on its financial status, comprehensive modular services portfolio, recent collaborations, information on capability / facility expansionsand an informed future outlook.
  • An analysis of the most active regions based on the locations of modular manufacturing solution providers; the report contains schematic representations of world maps that clearly indicate the modular facility / cleanroom manufacturing hubs.
  • A review of emerging trends, including the combination of single use technologies / continuous processing technologies with modular facilities, the shift to using smaller, multi-purpose and multi-product modular facilities.
  • A discussion on key points that should be considered to facilitate the shift from using conventional facilities to modular facilities. We have provided a case study on JHL Biotech’s KUBio biomanufacturing facility, which was constructed by GE Healthcare Life Sciences in China.
  • A detailed discussion on the various growth drivers, such as the development of personalized medicines, biosimilars, orphan drugs, and the anticipated increase in adoption of modular solutions in emerging markets and by pharmaceutical / biopharmaceutical CMOs.
  • A detailed analysis of the collaborations and agreements, covering facility construction agreements, service alliances and acquisitions, which have been established amongst various stakeholders in the past few years.

 

The study features a detailed analysis on the likely evolution of the pharmaceutical / biotechnology modular manufacturing market over the time period 2017 to 2030. We have provided insights on the expected growth of the market in different regions, including North America, Europe, Asia Pacific and rest of the world. In addition, we have segmented the likely evolution of the market on the basis of type of construction component(process equipment, base building, mechanical, electrical, process utilities, process piping and others), size of the facility (small-sized, mid-sized and large-sized), type of product (small molecules, biologics and others), purpose of facility (manufacturing facility, R&D facility and others) and type of facility (new facility and expansions). In order to account for the uncertainties associated with some of the parameters used and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market’s evolution.

 

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. The opinions and insights presented in the report were also influenced by discussions with senior stakeholders in the industry. The report presents detailed transcripts of discussions held with Maik Jornitz (CEO, G-CON Manufacturing), Pär Almhem (President, ModWave), Sulogna Roy (Business Development Engineer, Zeton) and Vernon Solomon (President, Environmental Systems Corporation).

 

 

Example Highlights

  1. During the course of our study, we identified close to 20 companies that offer modular facilities to pharmaceutical / biotechnology industry. Majority of these companies are located in North America and Europe. Examples of players based in these regions include (in alphabetical order) Biologics Modular, G-CON Manufacturing, GE Healthcare Life Sciences, Germfree Laboratories, IPM Technologies, Jacobs Engineering Group, KeyPlants, ModWave, NNE, Pharmadule Morimatsu and WH Partnership.
  2. In addition, there are a number of players that specialize in providing modular cleanrooms; during our research, we identified more than 160 such companies. Of these, there are several companies that solely focus on serving the pharmaceutical and biotechnology industries; examples include (in alphabetical order, no specific shortlisting criteria) American Cleanroom Systems, Asgard Cleanroom Solutions, AWS BIO PHARMA Technologies, CID Associates, Clean Air Flow, Clean Room Depot, Environmental Systems Corporation, Modulus Cleanrooms and Shanghai HJ Modular Cleanroom.
  3. Several pharmaceutical and biotechnology companies have adopted the modular concept for constructing new facilities or expanding existing infrastructure. Examples of some established companies include (in alphabetical order) AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, Merck, Roche, Novartis and Sanofi. Additionally, small to mid-sized companies that have installed modular facilities include (in alphabetical order) 3P Biotherapeutics, JHL Biotech, Just Biotherapeutics, Stragen Pharma and Strike Bio. In fact, in May 2016, JHL Biotech inaugurated a 2,400 square meters new manufacturing facility, based on the modular KUBio™ platform of GE Healthcare Sciences, at its site in Wuhan, China. More recently, in March 2017, Just Biotherapeutics contracted G-CON Manufacturing for the construction of a cGMP biologics facility in the Hangzhou Economic and Technology Development Area (HEDA) in China. The facility is currently under construction and is anticipated to be completed and operational in early 2018.
  4. A number of strategic collaborations have been inked in this domain. We came across over 35 collaborations established during the period 2014-H12017. Majority (~80%) of these collaborations are facility construction agreements. Prominent pharmaceutical / biotechnology modular facility or cleanroom providers that have entered into multiple partnerships include G-CON Manufacturing, GE Healthcare Life Sciences, AES Technology, M+W Group, and Pharmadule Morimatsu.
  5. Companies manufacturing niche and emerging therapeutic classes, such as personalized therapies, along with the rising number of biosimilars, hold significant promise for modular facility manufacturers. The adoption of such facilities is also likely to increase in emerging regions, some of which have struggled to meet GMP standards. In addition, CMOs, adopting modular facilities to reduce initial capital investment and handle multiple products, are expected to create incremental business opportunities for modular facility manufacturers.
  6. The pharmaceutical / biotechnology modular facilities market is anticipated to grow at an annualized rate of 8.9% during the period 2017 - 2030. Modular facilities for biologics manufacturing are expected to dominate (with more than 80% share) the market. Further, 85% of the overall market share is accounted for by facilities being used for manufacturing purposes. This is followed by facilities for R&D applications (12% of the overall market). In terms of type of facility, the opportunity is likely to be driven by construction of new facilities (65%) followed by modular expansions projects that will likely account for the remaining 35% of the market’s share.

 

 

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market till 2030, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

 

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the current state of the market and its likely evolution in the mid-long term.

 

Chapter 3 provides a general overview of the modular design concept with information on its historical evolution, types of modules and the modular construction process. It also provides details related to the construction of modular facilities for use in the pharmaceutical / biotechnology industry along with the advantages of these facilities, and information on modular cleanrooms, including their classification and prevalent cleanroom standards.

 

Chapter 4 includes a comprehensive overview of the landscape of companies that offer pharmaceutical / biotechnology modular facilities. It features an analysis of these service providers on the basis of their geographical location, establishment year, company size and the type of industry served. Additionally, it contains information on regulatory certifications and examples of recent projects undertaken by these companies.

 

Chapter 5 features a comprehensive overview of the landscape of companies that specialize in offering modular cleanrooms. It features an analysis of the modular cleanroom providers on the basis of their geographical location, type of industry served and the type of modular cleanrooms offered. The chapter also provides information on the components of modular cleanrooms provided by different companies and regulatory certifications of these firms.

 

Chapter 6 contains detailed profiles of some of the key players that are actively providing modular facilities to pharmaceutical and biotechnology companies. Each company profile includes a brief overview of the company, financial information (if available), details on service offerings, recent developments and an informed future outlook.

 

Chapter 7 features an elaborate discussion and analysis of the collaborations and partnerships that have been inked amongst players in this market over the last five years (2012 - August 2017). We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this domain. It also lists other recent developments, such as facility / capability expansions and certifications, which have taken place in this domain.

 

Chapter 8 provides insights on the recent trends in the pharmaceutical / biotechnology industry that are expected to influence the adoption of modular facilities. Some of these trends include the integration of single use / continuous processing technologies with modular facilities, emergence of smaller, multi-purpose, multi-product modular facilities, and collaborations that have been established to provide integrated and flexible modular solutions.

 

Chapter 9 features a detailed discussion on potential areas, such as rise of personalized medicines, biosimilars and orphan drugs, and increasing adoption of modular solutions in emerging regions and CMOs, which are likely to act as growth drivers in the pharmaceutical / biotechnology modular facilities market, during the coming years.

 

Chapter 10 presents details on some modular facilities built by various pharmaceutical / biotechnology companies across different geographies. It also includes a discussion on why modular facilities may be preferred over traditional facilities in the long term. Additionally, the chapter includes a case study on JHL Biotech’s recent installation of GE Healthcare Life Sciences’ KUBio modular biomanufacturing facility, at the former company’s site in Wuhan, China.

 

Chapter 11 presents a comprehensivemarket forecast analysis, highlighting the future potential of the pharmaceutical / biotechnology modular facilities market till the year 2030. We have segregated the opportunity on the basis of type of construction component, size of the facility, type of product, purpose of facility and type of facility. Our estimates are backed by robust analysis of data procured from both secondary and primary sources.

 

Chapter 12 summarizes the overall report. It presents a list of key takeaways and offers our independent opinion on the current scenario and evolutionary trends that are likely to determine the future of this market in the mid-long term.

 

Chapter 13 is a collection of transcripts of discussions that were held with key stakeholders in this market.We have presented the details of interviews held with Maik Jornitz (CEO, G-CON Manufacturing), Pär Almhem (President, ModWave), Sulogna Roy (Business Development Engineer, Zeton) and Vernon Solomon (President, Environmental Systems Corporation).

 

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

 

Chapter 15 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

 

 
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Modular Facilities in Pharmaceutical / Biotechnology Industry
3.1. Chapter Overview
3.2. Historical Background
3.3. The Concept of Modularization
3.3.1. Types of Modules
3.3.2. Modular Construction Process
3.4. Modular Construction in the Pharmaceutical Industry
3.4.1. Advantages of Modular Construction in the Pharmaceutical Industry
3.4.2. Pharmaceutical Modular Cleanrooms
3.4.2.1. Cleanroom Classifications and Standards
3.4.2.2. Advantages of Modular Cleanrooms
3.4.3. Regulations and Standards Concerning Modular Cleanroom Construction
 
4. Market Landscape of Modular Facility Manufacturers in Pharmaceutical / Biotechnology Industry
4.1. Chapter Overview
4.2. Modular Facility Manufacturers: Overall Market Landscape
4.2.1 Modular Facility Manufacturers: Distribution by Geography
4.2.2. Modular Facility Manufacturers: Analysis by Year of Establishment
4.2.3. Modular Facility Manufacturers: Distribution by Company Size
4.2.4. Modular Facility Manufacturers: Distribution by Type of Industry Served
4.2.5. Modular Facility Manufacturers: Regulatory Approvals and Certifications
4.2.6. Modular Facility Manufacturers: Modular Projects Executed / Undertaken
 
5. Market Landscape of Modular Cleanroom Providers in Pharmaceutical / Biotechnology Industry
5.1. Chapter Overview
5.2. Modular Cleanroom Providers: Overall Market Landscape
5.2.1. Modular Cleanroom Providers: Distribution by Geography
5.2.2. Modular Cleanroom Providers: Distribution by Type of Industry Served 
5.2.3. Modular Cleanroom Providers: Distribution by Type of Modular Cleanrooms Offered
5.2.4. Modular Cleanroom Providers: Type of Cleanroom Components Offered
5.2.5. Modular Cleanroom Providers: Regulatory Approvals and Certifications
5.3. Modular Cleanroom Component Providers
 
6. Pharmaceutical / Biotechnology Modular Facilities: Key Solution Providers
6.1. Chapter Overview
 
6.2. GE Healthcare Life Sciences
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Modular Facility Offerings
6.2.4. Recent Developments
6.2.5. Future Outlook
 
6.3. G-CON Manufacturing
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Modular Facility Offerings
6.3.4. Recent Developments
6.3.5. Future Outlook
 
6.4. Pharmadule Morimatsu
6.4.1. Company Overview
6.4.2. Modular Facility Offerings
6.4.3. Recent Developments
6.4.4. Future Outlook
 
6.5. ModWave and KeyPlants
6.5.1. Company Overview
6.5.2. Modular Facility Offerings
6.5.3. Recent Developments
6.5.4. Future Outlook
 
6.6. Jacobs Engineering Group
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Modular Facility Offerings
6.6.4. Recent Developments
6.6.5. Future Outlook
 
6.7. NNE
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Modular Facility Offerings
6.7.4. Recent Developments
6.7.5. Future Outlook
 
6.8. IPM Technologies
6.8.1. Company Overview
6.8.2. Modular Facility Offerings
6.8.3. Recent Developments
6.8.4. Future Outlook
 
6.9. Germfree Laboratories
6.9.1. Company Overview
6.9.2. Modular Facility Offerings
6.9.3. Future Outlook
 
6.10. Biologics Modular
6.10.1. Company Overview
6.10.2. Modular Facility Offerings
6.10.3. Recent Developments
6.10.4. Future Outlook
 
6.11. WH Partnership
6.11.1. Company Overview
6.11.2. Modular Facility Offerings
6.11.3. Recent Developments
6.11.4. Future Outlook
 
7. Partnerships and Other Recent Developments 
7.1. Chapter Overview
7.2. Partnership Models
7.3. Modular Facilities: List of Partnerships
7.3.1. Modular Facilities: Distribution of Partnerships by Year
7.3.2. Modular Facilities: Distribution of Partnerships by Type
7.3.3. Modular Facilities: Distribution of Partnerships by Geography
7.3.4. Modular Facilities: Leading Players by Number of Partnerships
7.4. Other Recent Developments
 
8. Recent Trends in Modular Facility Solutions 
8.1. Chapter Overview
8.2. The Pharmaceutical Industry is Rapidly Adopting the Use of Smaller, Modular Facilities
8.3. The Integration of Single Use Technologies with Modular Facilities Offers Flexibility as well as Economic Benefits
8.4. Continuous Processing Technologies Offer Added Advantages to the Modular Approach
8.5. The Market is Abuzz with Partnership Activity as Service Providers are Entering into Strategic Alliances in Order to Expand their Service Portfolios
 
9. Future Growth Opportunities
9.1. Chapter Overview
9.2. Small Scale Facilities for Personalized Therapies are Likely to Emerge as a Key Growth Driver in the Long Term
9.3. In Order to Accelerate Time to Market and Stay Competitive, Several Biosimilar Manufacturers are Expected to Install Modular Facilities
9.4. Addressing the Niche Requirements, Orphan Indications Offer Additional Opportunities for Modular Facility Manufacturers
9.5. Emerging Regions are Likely to be Attractive Markets for Players in the Long Term
9.6. Expansions of Existing Facilities Using Modular Solutions are Projected to Increase Significantly
9.7. Several Contract Manufacturing Organizations are Gradually Shifting Towards Using Modular Solutions 
 
10. Feasibility Study for Modular Facilities in Pharmaceutical / Biotechnology Industry
10.1. Chapter Overview
10.2. Modular Facility Projects Undertaken in the Pharmaceutical / Biotechnology Industry
10.3. Key Advantages of Modular Facilities
10.3.1. Rapid Construction Timelines of such Facilities Result in a Low-risk Investment
10.3.2. Despite the High Initial Investment, Modular Facilities Guarantee High Returns
 
10.4. Case Study: Modular Facility Based on KUBio Platform 
10.4.1. GE Healthcare’s KUBio Platform: Overview
10.4.2. JHL Biotech’s KUBio Modular Project in China: Overview and Construction Details
 
11. Opportunity Analysis for the Global Pharmaceutical / Biotechnology Modular Solutions Market
11.1. Chapter Overview
11.2. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Historical Data, 2014-August 2017
11.2.1. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Number of Facilities Per Year, 2014-August 2017
11.2.2. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Type of Facility, 2014-August 2017
11.2.3. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Geography, 2014-August 2017
11.2.4. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Purpose of Facility, 2014-August 2017
11.2.5. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Investment, 2014-August 2017
11.2.6. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies):  Distribution by Size of the Facility, 2014-August 2017
 
11.3. Forecast Methodology
11.4. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030
11.4.1. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component
11.4.2. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility
11.4.3. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography
11.4.4. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured
11.4.5. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility
11.4.6. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility
 
12. Conclusion
12.1. The Pharmaceutical / Biotechnology Industry is Witnessing an Increasing Need for Flexible, Modular Facilities
12.2. The Landscape of Companies Offering a Wide Range of Modular Solutions Has Evolved Considerably Over the Last Decade
12.3. Several Modular Cleanroom Providers are also Playing a Pivotal Role in the Market’s Evolution
12.4. Owing to the Benefits Offered by Modular Facilities, Their Adoption has Gradually Risen
12.5. The Growing Interest in Modular Facilities has Recently Led to the Establishment of Several Key Collaborations
12.6. The Integration of Emerging Technologies with Modular Solutions has Redefined the Applicability and Preferences for Modular Facilities
12.7. Overall, the Market is Anticipated to Witness Significant Growth in the Coming Decade
12.8. Concluding Remarks
 
13. Interview Transcripts
13.1. Chapter Overview
13.2. Maik Jornitz, CEO, G-CON Manufacturing
13.3. Pär Almhem, President, ModWave
13.4. Sulogna Roy, Business Development Engineer, Zeton
13.5. Vernon Solomon, President, Environmental Systems Corporation
 
14. Appendix 1:  Tabulated Data
 
15. Appendix 2: List of Companies and Organizations
 
 
Figure 3.1 Modular Construction: Applications
 
Figure 3.2 Modular Construction: Processes Involved
 
Figure 3.3 Modular and Conventional Buildings: Construction Timelines
 
Figure 3.4 Modular Construction: Advantages
 
Figure 4.1  Modular Facility Manufacturers: Distribution by Geography
 
Figure 4.2 Modular Facility Manufacturers: Cumulative Number of Companies by Year of Establishment
 
Figure 4.3 Modular Facility Manufacturers: Distribution by Company Size
 
Figure 4.4 Modular Facility Manufacturers: Distribution by Type of Industry Served
 
Figure 5.1 Modular Cleanroom Providers: Distribution by Geography
 
Figure 5.2 Modular Cleanroom Providers: Distribution by Type of Industry Served
 
Figure 5.3 Modular Cleanroom Providers: Distribution by Type of Cleanrooms Provided
 
Figure 6.1 GE Healthcare Life Sciences: Key Operations
 
Figure 6.2 GE Healthcare: Revenues, 2012-2016 (USD Billion)
 
Figure 6.3 GE Healthcare: Revenues by Business Divisions, 2016 (USD Billion)
 
Figure 6.4 G-CON Manufacturing: Types of PODs Offered
 
Figure 6.5 G-CON Manufacturing: Features of the Standard PODs
 
Figure 6.6 G-CON Manufacturing: Applications of PODs
 
Figure 6.7 Pharmadule Morimatsu: Modular Facility Fabrication Process
 
Figure 6.8 KeyPlants: Advantages of Modular Facility
 
Figure 6.9 Jacobs Engineering Group: Revenues, 2012-Q3 2017 (USD Billion)
 
Figure 6.10 Jacobs Engineering Group: Revenues by Services Offered, 2016 (USD Billion)
 
Figure 6.11 Jacobs Engineering Group: Revenues by Business Divisions, 2016 (USD Billion)
 
Figure 6.12 NNE: Services Portfolio
 
Figure 6.13 NNE: Annual Revenues, 2012-2016 (DKK Million)
 
Figure 6.14  NNE: Advantages of Bio on Demand Facility
 
Figure 6.15 IPM Technologies: Applications of Modular Facilities
 
Figure 6.16 Germfree Laboratories: Types and Applications of Modular Facilities Offered
 
Figure 6.17 Germfree Laboratories: Types of BioPharma Lab Modules
 
Figure 7.1 Modular Facilities: Cumulative Number of Partnerships by Year (2012-2017)
 
Figure 7.2 Modular Facilities: Distribution by Type of Partnerships
 
Figure 7.3 Modular Facilities: Distribution of Partnerships by Geography
 
Figure 7.4 Modular Facilities: Leading Players by Number of Partnerships
 
Figure 9.1 Modular Facilities Market: Future Growth Opportunities
 
Figure 10.1 Modular Facilities: Distribution by Company and Location
 
Figure 10.2 Modular Facilities: Example Manufacturers Along with their Clients
 
Figure 10.3 Traditional and Modular Facilities: Analysis of Risk and Probability of Success Across Different Phases of Product Development
 
Figure 10.4 Conventional and Modular Facilities: Comparison of Construction Timelines
 
Figure 10.5 JHL Biotech’s KUBio Manufacturing Facility: Construction Process
 
Figure 10.6 KUBio Facility: Construction Timeline
 
Figure 11.1 Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Number of Facilities Per Year, 2014-August 2017
 
Figure 11.2 Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Type of Facility, 2014-August 2017
 
Figure 11.3 Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Geography, 2014-August 2017
 
Figure 11.4 Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Type of Facility, 2014-August 2017
 
Figure 11.5 Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Investment (USD Million), 2014-August 2017
 
Figure 11.6 Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Size of the Facility (sq ft), 2014- August 2017
 
Figure 11.7 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Base Scenario (USD Billion)
 
Figure 11.8 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component, Base Scenario (USD Billion)
 
Figure 11.9 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility, Base Scenario (USD Billion)
 
Figure 11.10 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017, 2025 and 2030: Distribution by Geography (%)
 
Figure 11.11 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography, Base Scenario (USD Billion)
 
Figure 11.12 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured, Base Scenario (USD Billion)
 
Figure 11.13 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility, Base Scenario (USD Billion)
 
Figure 11.14 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility, Base Scenario (USD Billion)
 
Figure 12.1 Global Pharmaceutical / Biotechnology Modular Facilities Market: 2017, 2025 and 2030 (USD Billion)
 
 
Table 3.1 Cleanrooms Classification Standards
 
Table 3.2 ISO and FED STD 209E: Cleanroom Classification
 
Table 4.1 Modular Facility Manufacturers
 
Table 4.2 Modular Facility Manufacturers: Distribution by Type of Industry Served
 
Table 4.3 Modular Facility Manufacturers: Regulatory Approvals and Certifications 
 
Table 4.4 Modular Facility Manufacturers: Modular Projects Executed / Undertaken
 
Table 5.1 Modular Cleanroom Providers
 
Table 5.2 Modular Cleanroom Providers: Distribution by Type of Industry Served
 
Table 5.3 Modular Cleanroom Providers: Distribution by Type of Modular Cleanrooms Offered
 
Table 5.4 Modular Cleanroom Providers: Distribution by Type of Cleanroom Components Offered
 
Table 5.5 Modular Cleanroom Providers: Regulatory Approvals and Certifications 
 
Table 5.6 Modular Cleanroom Component Providers
 
Table 6.1 Modular Manufacturing Facility Providers: List of Companies Profiled
 
Table 6.2 GE Healthcare Life Sciences: KUBio Facility Configurations
 
Table 6.3 G-CON Manufacturing: Dimensions of Standard PODs
 
Table 6.4 Pharmadule Morimatsu: Modular Projects Undertaken
 
Table 6.5 KeyPlants: Modular Projects Undertaken
 
Table 6.6 Jacobs Engineering Group: Pharma Modular Projects Undertaken
 
Table 6.7 NNE: Key Details of API Drug Substance Facility
 
Table 6.8 NNE: Key Details of Final Drug Product Facility
 
Table 6.9 IPM Technologies: Production Capacities of Modular Facilities
 
Table 6.10 Germfree Laboratories: Advantages of BioPharma Modules
 
Table 6.11 Germfree Laboratories: Advantages of BioPharma Lab Modules
 
Table 6.12 Biologics Modular: Features of Modular Cleanrooms
 
Table 6.13 Biologics Modular: Features of Modular Analytical Laboratories and Biorepositories
 
Table 7.1 Modular Facility Manufacturers: Partnerships
 
Table 7.2 Modular Facilities: List of Expansions and Certifications
 
Table 10.1 Modular Facilities: Distribution by Company and Location 
 
Table 10.2 PODs, Modular and Conventional Facilities: Comparison of Construction Investment and Financial Returns
 
Table 11.1 Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Historical Data, 2014-August 2017
 
Table 14.1 Modular Facility Manufacturers: Cumulative Number of Companies by Establishment Year
 
Table 14.2 Modular Facility Manufacturers: Distribution by Company Size
 
Table 14.3 Modular Facility Manufacturers: Distribution by Type of Industry Served
 
Table 14.4 Modular Cleanroom Providers: Distribution by Type of Industry Served
 
Table 14.5 Modular Cleanroom Providers: Distribution by Type of Cleanrooms Offered
 
Table 14.6 GE Healthcare: Revenues, 2012-2016 (USD Billion)
 
Table 14.7 GE Healthcare: Revenues by Business Divisions, 2016 (USD Billion)
 
Table 14.8 Jacobs Engineering Group: Revenues, 2012-Q3 2017 (USD Billion)
 
Table 14.9 Jacobs Engineering Group: Revenues by Services Offered, 2016 (USD Billion)
 
Table 14.10 Jacobs Engineering Group: Revenues by Business Divisions, 2016 (USD Billion)
 
Table 14.11 NNE: Annual Revenues, 2012-2016 (DKK Million)
 
Table 14.12 Modular Facilities: Cumulative Number of Partnerships by Year (2012-2017)
 
Table 14.13 Modular Facilities: Distribution by Type of Partnerships
 
Table 14.14 Modular Facilities: Distribution of Partnerships by Geography
 
Table 14.15 Modular Facilities: Leading Players by Number of Partnerships
 
Table 14.16 Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Number of Facilities Per Year, 2014-August 2017
 
Table 14.17 Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Type of Facility, 2014-August 2017
 
Table 14.18 Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Geography, 2014-August 2017
 
Table 14.19 Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Purpose of Facility, 2014-August 2017
 
Table 14.20 Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Investment, 2014-August 2017 (USD Million)
 
Table 14.21 Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies):  Distribution by Size of the Facility, 2014-August 2017
 
Table 14.22 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Conservative Scenario (USD Billion)
 
Table 14.23 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Base Scenario (USD Billion)
 
Table 14.24 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Optimistic Scenario (USD Billion)
 
Table 14.25 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component, Conservative Scenario (USD Billion)
 
Table 14.26 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component, Base Scenario (USD Billion)
 
Table 14.27 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component, Optimistic Scenario (USD Billion)
 
Table 14.28 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility, Conservative Scenario (USD Billion)
 
Table 14.29 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility, Base Scenario (USD Billion)
 
Table 14.30 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility, Optimistic Scenario (USD Billion)
 
Table 14.31 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography (%)
 
Table 14.32 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography, Conservative Scenario (USD Billion)
 
Table 14.33 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography, Base Scenario (USD Billion)
 
Table 14.34 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography, Optimistic Scenario (USD Billion)
 
Table 14.35 Global  Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured, Conservative Scenario (USD Billion)
 
Table 14.36 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured, Base Scenario (USD Billion)
 
Table 14.37 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured, Optimistic Scenario (USD Billion)
 
Table 14.38 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility, Conservative Scenario (USD Billion)
 
Table 14.39 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility, Base Scenario (USD Billion)
 
Table 14.40 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility, Optimistic Scenario (USD Billion)
 
Table 14.41  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility, Conservative Scenario (USD Billion)
 
Table 14.42 Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility, Base Scenario (USD Billion)
 
Table 14.43  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility, Optimistic Scenario (USD Billion)
 
Table 14.44 Global Pharmaceutical / Biotechnology Modular Facilities Market: 2017, 2025 and 2030 (USD Billion)
 
 
The following companies and organizations have been mentioned in the report.
 
1. 209 Technologies
2. A&M Project Services
3. AASTHA CLEANROOM SYSTEMS
4. ABN Cleanroom Technology
5. Abtech
6. ACH Engineering
7. Acumen Technology
8. A.D. Cleanrooms Engineering
9. ADDvise
10. AES Clean Technology
11. Air Innovations
12. Airgas
13. Airology
14. Air Micron Cleantech
15. Aircare Projects 
16. Airtech Systems
17. AJNI Industries
18. Ajinomoto North America
19. AKERTEC
20. Albian Group 
21. Alembic Pharmaceuticals
22. Allied Cleanrooms
23. Alnylam Pharmaceuticals
24. AME For Industry
25. AM Cleanroom Build and Performance
26. American Cleanroom Systems
27. Angstrom Technology
28. Aqvida
29. Arthrex
30. Asgard Cleanroom Solutions
31. AstraZeneca
32. AWS BIO PHARMA TECHNOLOGIES 
33. Axenic Systems
34. Bangalore Air Tech Solution
35. Bassaire
36. Baxter
37. bc-technology
38. Belcher Equipment
39. Bode Equipment
40. BioCon Solutions 
41. Biogen
42. Bigneat
43. Bioinspection
44. Biologics Modular
45. Biosoft
46. Bouygues Energies & Services
47. Bristol-Myers Squibb
48. Broad Sustainable Building
49. Butler Manufacturing
50. Cambridge Cleanroom
51. CID Associates 
52. Cipharm
53. Clean Air Flow
54. Clean Air Products
55. Clean Air Systems
56. Clean Air Technology
57. Clean Modules
58. Cleanrooms Australia
59. Cleanroom Equipment
60. Cleanroom Solutions
61. ClearSphere
62. Clean Room Depot 
63. Clean Rooms International
64. Clean Rooms Plus
65. Clean Rooms West
66. Clean Zone Technology 
67. CleanAir Solutions
68. Cleanroom Ceiling Systems (a division of Varni Enterprises)
69. Cleanroom Results
70. Cleanroom Synergy 
71. Cleanrooms By United
72. CleanZones
73. CLEEMS
74. Clestra Cleanroom
75. Cook Imaging
76. Connect 2 Cleanrooms
77. CONSAB International
78. CRB Consulting Engineers
79. Design Filtration Microzone
80. Dortek Hygienic Doors
81. Dr. Reddy’s Laboratories
82. Dynamic Manufacturing Solutions
83. Ebtech Industrial Modular Building Solutions 
84. Eli Lilly
85. E- Pack Polymers
86. Enbloc
87. Environmental Systems Corporation
88. Envair Electrodyne
89. Fabtech Technologies International
90. Filtration Technology 
91. Firmament Technology
92. Florida Cleanroom Systems
93. Foothills Systems
94. Flowstar 
95. Fluor
96. Galderma
97. Guardtech Cleanrooms
98. G-CON Manufacturing
99. GE Healthcare Life Sciences
100. Genentech
101. Gerbig Engineering Company
102. Germfree Laboratories
103. Gilcrest Manufacturing
104. GlaxoSmithKline
105. Glowmax Engineers
106. GMP Technical Solutions
107. GMPMax Pharma
108. Green Carrier Consultancy and Tech Solutions
109. Halco Products
110. Hectra Enviro Systems
111. Hemair Systems 
112. HEMCO Corporation
113. HEPAire Products Corporation
114. Hermetel Oy
115. Hodess Construction
116. Huntair
117. Iberconcept
118. Innclose
119. Innotech Products
120. Innovative Cleanroom Technologies
121. InPlant Offices
122. Instaspace
123. Integrated Clean Room Technologies
124. IPM Technologies
125. Isoflex Systems
126. IsoTech Design
127. Jacobs Engineering Group 
128. JHL Biotech
129. JMC Project Services
130. Just Biotherapeutics
131. KABTech Corporation
132. KeyPlants
133. Kingspan
134. Kleantech Engineering Systems
135. KTEC Cleanroom Systems
136. Labard Instruchem
137. Labover
138. Labworks International
139. Lasco Services
140. Lennox Clean Room Technologies
141. Liberty Industries
142. LifeTek Solutions
143. LM Air Technology
144. Longden Company
145. Lonza
146. Mabion
147. Mach-Aire
148. MAK Clean Air Systems
149. Mallinckrodt Pharmaceuticals
150. Mars Sterile Solutions
151. McDonald's
152. MDI
153. MECART
154. Medipharma
155. Merck
156. Merit Holdings
157. Microbinc
158. Microzone Corporation
159. MK Precision
160. Moduclean
161. Mobius Controlled Environments
162. Modubuild
163. Modulus Cleanrooms
164. Modular Cleanrooms
165. ModWave
166. Monmouth Scientific
167. Morimatsu Industry Group
168. M P Prime Structures
169. MRC Systems
170. MTX Contracts
171. M+W Group
172. Nano Clean
173. National Partitions
174. NextCell Pharma
175. NGS Cleanroom Solutions
176. Nicomac
177. NNE
178. Norwood Group
179. Novartis
180. Novo Nordisk
181. Octapharma
182. OCTANORM 
183. OSB Prefab Technologies
184. Pacific Environmental Technologies
185. Panel Built
186. Parteco
187. PC Company
188. Pfizer
189. PermaTherm
190. Pharmacia
191. Pharmacon
192. Pharmadule Morimatsu
193. Pharmintech Turnkey Solutions
194. Plascore
195. Poppleton
196. PortaFab
197. Porta-King Building Systems
198. Power And Motion
199. Precision Air Technology
200. Precision Cleanrooms
201. Precision Engineering design
202. ProCleanroom
203. Progenitor Cell Therapy  
204. QleanAir Scandinavia
205. Riddhi Metals
206. Rinac India
207. Robert Soper
208. Sartorius Stedim Biotech
209. Sapphire Cleanrooms
210. Sears Roebuck and Company
211. SCHILLING ENGINEERING
212. Schering-Plough
213. Shanghai HJ Modular Cleanroom
214. SRS Shelving + Rack Systems
215. Skylark Engineering Technologies
216. Simplex Isolation Systems
217. SML Clean Room Solutions
218. Solutions and Handling
219. Span Construction and Engineering
220. Srprefabs Modular Cleanroom
221. Starrco
222. Stefatos
223. Sterlitech
224. Stevenage BioScience Catalyst
225. Stodec Products
226. SUNBEL
227. Suntec Teknopak
228. Stragen Pharma
229. Swedish Modules
230. Synergy Thrislington
231. SZ Airkey Environmental Tech & Eng
232. Tabuk Pharmaceuticals
233. TCM (The Cleanroom Market)
234. Technical Air Products
235. Ted Thorsen Material Handling
236. Telstar Life Science Solutions
237. Termovent
238. Terra Universal
239. Teruisi Pharmaceutical
240. Teva Pharmaceutical
241. The Softwall Shop 
242. Travis Clean Air
243. Tudela International
244. Turnkey Modular Systems
245. Ultrapure Technology
246. United BioPharma
247. United Partition Systems
248. United Pharmaceuticals
249. University of Tennessee Health Science Center
250. Vanguard Modular Building Systems
251. Vernick & Associates
252. VRP CLEAN ROOM SYSTEMS
253. Weaver Technologies
254. Westbury Cleanrooms
255. Western Environmental Corporation
256. Whitenair Technologies
257. WH Partnership
258. w.w. Cannon
259. XBiotech
260. XCounter
261. Xytel
262. YRS Enterprises
263. Zeton
 

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security